|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
BioCryst Pharmaceuticals, Inc. is focused on designing, optimizing and developing novel small molecule pharmaceuticals that block key enzymes essential for cancer, cardiovascular diseases and viral infections. BCRX's most advanced drug candidate, BCX-1777, is an investigational purine nucleoside phosphorylase inhibitor for the treatment of T-cell mediated disorders. BCRX's TF/FVIIa inhibitor project has emerged as its highest priority discovery program. BCRX has designed and synthesized a group of compounds that are potent and selective inhibitors of the Tissue Factor/Factor VIIa and further optimization is ongoing. BCRX has also identified one compound, BCX-3607, for clinical development. The goal is to advance BCX-3607 into clinical development for treatment of unstable angina during 2003, while seeking a partner to develop and potentially commercialize this class of inhibitors.
Any thoughts on this biotech in Birmingham, Alabama?
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|